Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 11.75% | 4.94% | -1.66% | 5.97% | 30.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.75% | 4.94% | -1.66% | 5.97% | 30.74% |
| Cost of Revenue | 10.72% | 10.53% | 3.43% | 3.70% | 9.64% |
| Gross Profit | 12.17% | 2.17% | -4.31% | 7.13% | 42.55% |
| SG&A Expenses | -1.67% | 13.78% | 15.42% | 12.93% | 30.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.31% | 13.68% | 15.02% | 12.63% | 30.22% |
| Operating Income | 2.69% | -14.61% | -16.86% | -13.33% | -30.16% |
| Income Before Tax | 29.78% | 30.04% | -30.24% | -26.67% | -12.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.97% | 28.33% | -34.74% | -30.93% | -9.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.97% | 28.33% | -34.74% | -30.93% | -9.45% |
| EBIT | 2.69% | -14.61% | -16.86% | -13.33% | -30.16% |
| EBITDA | -0.18% | -18.26% | -19.76% | -15.03% | -33.17% |
| EPS Basic | 36.59% | 38.43% | -12.52% | 2.62% | 58.29% |
| Normalized Basic EPS | 12.70% | 1.36% | 5.64% | 22.49% | 45.14% |
| EPS Diluted | 37.16% | 38.86% | -11.40% | 4.36% | 58.08% |
| Normalized Diluted EPS | 12.70% | 1.36% | 5.64% | 22.49% | 45.14% |
| Average Basic Shares Outstanding | 13.12% | 17.75% | 24.05% | 34.47% | 64.26% |
| Average Diluted Shares Outstanding | 13.12% | 17.75% | 24.05% | 34.47% | 64.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |